Legal Representation
Attorney
Scott D. Woldow
USPTO Deadlines
Next Deadline
1102 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20230110)
Due Date
January 10, 2029
Grace Period Ends
July 10, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 10, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jan 10, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 25, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 25, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 5, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 20, 2022 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE | Loading... |
| Sep 16, 2022 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
| Sep 15, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 10, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Sep 10, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Sep 10, 2022 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Sep 10, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 16, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 16, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 16, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 7, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 8, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 8, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 8, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 1, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 18, 2021 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| Oct 18, 2021 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Sep 24, 2021 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Oct 14, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 3, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations for the treatment of respiratory conditions, namely, antibody for the treatment of Acute Respiratory Distress syndrome (ARDS), antibody for the treatment of Idiopathic Pulmonary Fibrosis (IPF), and Interstitial Lung Diseases (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, (HAE)
Classification
International Classes
005